Loefflers syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 11: Line 11:


===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The incidence/prevalence of Löffler syndrome is
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*The case-fatality rate/mortality rate of of Löffler syndrome is literally zero.
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].
*No deaths due to Löffler syndrome have been reported. Löffler syndrome is considered a benign, self-limiting disease without significant morbidity. Symptoms usually subside within 3-4 weeks or shortly after the offending medication is withdrawn in drug-induced pulmonary eosinophilia.


===Age===
===Age===

Revision as of 13:31, 16 May 2019


Löffler's syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Loefflers syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Loefflers syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Loefflers syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Loefflers syndrome epidemiology and demographics

CDC on Loefflers syndrome epidemiology and demographics

Loefflers syndrome epidemiology and demographics in the news

Blogs on Loefflers syndrome epidemiology and demographics

Directions to Hospitals Treating Loefflers syndrome

Risk calculators and risk factors for Loefflers syndrome epidemiology and demographics

Overview

Löffler syndrome is due to intestinal helminth infections with a pulmonary cycle which is distributed worldwide; nonetheless, parasitic infections such as Ancylostoma duodenale, Ascaris lumbricoides, Ascaris suum, Necator americanus, Strongyloides stercoralis are more prevalent in tropical areas particularly in communities with low socioeconomic status and poor sanitary conditions. In the United States, 20-67% of children in rural southern communities have been reported to suffer from ascariasis; Nevertheless, there are no specific statistics for the occurrence of Löffler syndrome. Globalization increased immigration, and travel warrants alertness of US physicians and the other health care works of developed countries, because an encounter with imported tropical diseases and thus the resulted Löffler syndrome could be more likely nowadays.

Epidemiology and Demographics

Incidence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

Prevalence

  • The incidence/prevalence of Löffler syndrome is
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
  • The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

  • The case-fatality rate/mortality rate of of Löffler syndrome is literally zero.
  • No deaths due to Löffler syndrome have been reported. Löffler syndrome is considered a benign, self-limiting disease without significant morbidity. Symptoms usually subside within 3-4 weeks or shortly after the offending medication is withdrawn in drug-induced pulmonary eosinophilia.

Age

  • Patients of all age groups may develop Löffler syndrome.
  • Nevertheless, Löffler syndrome more commonly affects young children.
  • A higher incidence of intestinal helminthiases and Löffler syndrome has been reported in young children because they are more exposed to contaminated soil and because young children exhibit hand-to-mouth behavior more often than adults

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

Template:WH Template:WS